Prescribing information

 

    

EXJADE offers simple and convenient dosing for your patients compared with previous formulations.1–3

 Icons showing the dosing and administration instructions for EXJADE

is taken once-daily1,2

 Icons showing the dosing and administration instructions for EXJADE

does not contain lactose or sodium lauryl sulphate2

 Icons showing the dosing and administration instructions for EXJADE

can be taken on an empty stomach or with a light meal1,2

 Icons showing the dosing and administration instructions for EXJADE

should be swallowed whole or may be fully crushed*1,2

 

 

*If crushed, tablets must be immediately and completely consumed.

 

EXJADE may be used for the treatment of:

Transfusional iron overload in patients with MDS, SCD and thalassaemia1,2

MDS, SCD and thalassaemia are a group of blood disorders that can lead to anaemia as a result of a deficiency in Hb or healthy RBCs in the blood. Repeated blood transfusions can be used as a treatment in order to prevent this deficiency, however this can lead to the build-up of excess iron known as iron overload.4

Iron overload in patients with non-transfusional thalassaemia1,2

Patients with non-transfusion-dependent thalassaemia syndromes have a heightened absorption of dietary iron. This takes place within the GI tract and is a cause of iron overload.4

It is important to control levels of excess iron in order to avoid the toxic effects of iron build-up. This can be achieved using medications known as iron chelators, such as EXJADE. EXJADE has the ability to bind to excess iron to form an iron-complex. This complex can then be easily excreted and removed by the body.4

Please refer to the SmPC for the licensed indication and further information.

EXJADE is available as a simplified, convenient, once-daily FCT1,2

EXJADE FCT is available in 3 strengths:2

Icons showing the dosing and administration instructions for EXJADE

This range in tablet strength allows for iron-overloaded patients to have a dose tuned to their needs.

Dosing schedule and dose adjustment steps vary depending on indication. The recommended dosing schedules for patients with transfusional iron overload and non-transfusion-dependent thalassaemia syndromes are available on this website and can be viewed via the links below or via the SmPC.

 

Abbreviations: FCT, film-coated tablets; GI, gastrointestinal; Hb, haemoglobin; ICT, iron chelation therapy; MDS, myelodysplastic syndromes; RBC, red blood cell; SCD, sickle cell disease; SmPC, Summary of Product Characteristics.

References

  1. EXJADE® dispersible tablets summary of product characteristics.
  2. EXJADE® film-coated tablets summary of product characteristics.
  3. Taher A, et al. New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, Phase II ECLIPSE study. Am J Hematol 2017;92(5):420–428.
  4. Cappellini MD, et al. Guidelines for the management of transfusion dependent thalassaemia (TDT). 3rd ed. Nicosia, Cyprus: Thalassaemia International Federation; 2014.
HCP20-C005i June 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]